Last checked at 13 Aug 2019 11:16
13 August 2019
N4 Pharma Plc
("N4 Pharma" or the "Company")
Holdings in Company
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, announces that it has been notified that, following a purchase of 112,258 ordinary shares of 0.4p each in the company ("Ordinary Shares") earlier today, Mr David Farrier is now beneficially interested in 12,175,510 Ordinary Shares, representing 12.0 per cent. of the Company's issued share capital.
Enquiries:
N4 Pharma Plc Nigel Theobald, CEO |
Via Scott PR
|
Allenby Capital Limited James Reeve/Asha Chotai
| Tel: +44(0)203 328 5656 |
Scott PR Georgia Smith
|
Tel: +44(0)1477 539 539
|
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.